Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbisko CaymanFRA:8ZD -0.84%55 Quick Ratio is 4.98 as of Dec. 2025, which is 73% below its 10-year median of 18.70. GuruFocus rates FRA:8ZD with a GF Score™ of 55/100 and a GF Value™ of €1.38 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Abbisko Cayman ranks better than 60.11% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Abbisko Cayman's quick ratio for the quarter that ended in Dec. 2025 was 4.98.
Abbisko Cayman has a quick ratio of 4.98. It generally indicates good short-term financial strength.
The historical rank and industry rank for Abbisko Cayman's Quick Ratio or its related term are showing as below:
FRA:8ZD'
s Quick Ratio Range Over the Past 10 Years
Min: 4.98 Med: 18.7 Max: 35.1
Current: 4.98
During the past 7 years, Abbisko Cayman's highest Quick Ratio was 35.10. The lowest was 4.98. And the median was 18.70.
FRA:8ZD's Quick Ratio is ranked better than 60.11% of 1409
companies
in the Biotechnology industry
Industry Median: 3.54
vs FRA:8ZD: 4.98
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Abbisko Cayman Quick Ratio Related Terms
Abbisko Cayman Quick Ratio Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8ZD vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, Abbisko Cayman's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Abbisko Cayman's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (FRA:8ZD) has a Quick Ratio of 4.98 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Abbisko Cayman and its competitors. This is 73% below median its historical median of 18.70. Over the past decade, Abbisko Cayman's Quick Ratio has ranged from 4.98 to 35.10. According to the industry distribution chart, Abbisko Cayman ranks #562 out of 1409 companies in the Biotechnology industry, placing it in the top 39.9%.
Is Abbisko Cayman's Quick Ratio too high?
Abbisko Cayman's current Quick Ratio of 4.98 is 73% below median its 10-year median of 18.70. Over the past 10 years, this metric has ranged from a low of 4.98 to a high of 35.10. The Biotechnology industry median Quick Ratio is 3.54. Abbisko Cayman's value of 4.98 is 40.7% above this industry median. Based on the distribution chart, Abbisko Cayman ranks #562 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abbisko Cayman has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #562 out of 1409 companies for Quick Ratio. This puts Abbisko Cayman in the upper half of its industry. The industry median Quick Ratio is 3.54. Abbisko Cayman's value of 4.98 is 40.7% above this benchmark. Historically, Abbisko Cayman's own Quick Ratio has ranged from 4.98 to 35.10 over the past decade. While the company's 10-year median is 18.70 vs. the industry median of 3.54, Abbisko Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.54, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbisko Cayman's current Quick Ratio of 4.98 is 40.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Abbisko Cayman and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbisko Cayman's current Quick Ratio is 4.98, which is 73% below median its own 10-year median of 18.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (FRA:8ZD) is currently considered Fairly Valued. The stock's GF Value™ is €1.38, compared to a current price of €1.18 — trading 14.5% below its estimated fair value. The current Quick Ratio is 4.98, which is 73% below median its 10-year median of 18.70 and 40.7% above the Biotechnology industry median of 3.54. Abbisko Cayman's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Abbisko Cayman (FRA:8ZD), the current Quick Ratio is 4.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (FRA:8ZD) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of €1.18 is trading 14.5% below its estimated GF Value™ of €1.38.
GuruFocus considers Abbisko Cayman to be Fairly Valued.
Key valuation signals for FRA:8ZD:
Quick Ratio: 4.98 (73% below median its 10-year median of 18.70)
GF Value™: €1.38 vs. price of €1.18 (14.5% below fair value)
Industry Position: 40.7% above the Biotechnology median (#562 of 1409)
No single metric tells the full story. See the FRA:8ZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
55GF Score
Get the complete analysis for FRA:8ZD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8ZD has been successfully added to your 
